Andrew MacGinnitie

Andrew MacGinnitie, MD, PhD

Clinical Director, Division of Immunology

Assistant Professor of Pediatrics, Harvard Medical School

    Contact: 617-355-6117
  • Fax: 617-730-0310

Medical Services


  • Food Allergy
  • Asthma
  • Hereditary Angioedema
  • Allergic Rhinitis
  • Urticaria
  • Drug Allergy
  • Immunodeficiency
  • Eczema
  • Recurrent Infections


  • Allergy Immunology


  • English


  • Allergy Program
  • Primary Immunodeficiency Disorders Program
  • Immunology Program
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Experience and Education



Yale University,

New Haven, CT


University of Chicago, Pritzker School of Medicine,

Chicago, IL


University of Chicago, 1996

Chicago, IL

Allergy Immunology

Boston Children's Hospital , 2001-2004

Boston, Ma


Boston Combined Residency Program, 1998-1999

Boston, Ma


Boston Combined Residency Program, 1999-2004

Boston, Ma


  • American Board of Allergy and Immunology


Publications powered by Harvard Catalyst Profiles
  1. Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, Leonard SA, Laubach SS, Kim EH, Vickery BP, Davis BP, Heimall J, Cianferoni A, MacGinnitie AJ, Crestani E, Burks AW. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. J Allergy Clin Immunol Pract. 2017 Oct 30.
  2. Akuete K, Guffey D, Israelsen RB, Broyles JM, Higgins LJ, Green TD, Naimi DR, MacGinnitie AJ, Vitalpur G, Minard CG, Davis CM. Multicenter prevalence of anaphylaxis in clinic-based oral food challenges. Ann Allergy Asthma Immunol. 2017 10; 119(4):339-348.e1.
  3. MacGinnite A. Update on Potential Therapies for IgE-Mediated Food Allergy. Curr Allergy Asthma Rep. 2017 Jan; 17(1):4.
  4. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, Heimall J, Makhija M, Robison R, Chinthrajah RS, Lee J, Lebovidge J, Dominguez T, Rooney C, Lewis MO, Koss J, Burke-Roberts E, Chin K, Logvinenko T, Pongracic JA, Umetsu DT, Spergel J, Nadeau KC, Schneider LC. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8.
  5. Simberloff T, Parambi R, Bartnikas LM, Broyles AD, Hamel V, Timmons KG, Miller DM, Graham DA, Schneider LC, MacGinnitie AJ. Implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) for Food Challenges. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2):335-344.e3.
  6. Levy S, Dedeoglu F, Gaffin JM, Garvey KC, Harstad E, MacGinnitie A, Rufo PA, Huang Q, Ziemnik RE, Wisk LE, Weitzman ER. A Screening Tool for Assessing Alcohol Use Risk among Medically Vulnerable Youth. PLoS One. 2016; 11(5):e0156240.
  7. Craig TJ, Schneider LC, MacGinnitie AJ. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015 Sep; 26(6):537-44.
  8. Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015 Mar-Apr; 3(2):206-212.e4.
  9. MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug; 25(5):420-7.
  10. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013 Aug; 132(2):e490-7.
  11. Show all
  12. Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013 Mar-Apr; 34(2):155-61.
  13. Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):168-72.
  14. Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013 Mar; 110(3):184-188.e2.
  15. Jacobs TS, Jones BL, MacGinnitie AJ. Long-acting beta-agonists and the risk of intensive care unit admission in children. J Asthma. 2012 Jun; 49(5):450-5.
  16. MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc. 2012 Mar-Apr; 33(2):178-85.
  17. Ruffner MA, Finegold DN, MacGinnitie AJ. Infant with unusual food reactions. Acta Paediatr. 2011 Oct; 100(10):1289, 1394-5.
  18. McHugh BM, MacGinnitie AJ. Indoor allergen sensitization and the risk of asthma and eczema in children in Pittsburgh. Allergy Asthma Proc. 2011 Sep-Oct; 32(5):372-6.
  19. Burke S, Petrov A, Johnson J, MacGinnitie A. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis. Ann Allergy Asthma Immunol. 2011 Aug; 107(2):181-2.
  20. MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011 Nov; 22(7):671-5.
  21. Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol. 2011 Jan; 127(1):264-5.
  22. MacGinnitie A. In utero anaphylaxis. Med Hypotheses. 2011 Jan; 76(1):70-2.
  23. He R, Kim HY, Yoon J, Oyoshi MK, MacGinnitie A, Goya S, Freyschmidt EJ, Bryce P, McKenzie AN, Umetsu DT, Oettgen HC, Geha RS. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol. 2009 Oct; 124(4):761-70.e1.
  24. Puglisi G, Netravali MA, MacGinnitie AJ, Bonagura VR. 11q terminal deletion disorder and common variable immunodeficiency. Ann Allergy Asthma Immunol. 2009 Sep; 103(3):267-8.
  25. Scholnicoff ET, MacGinnitie AJ, Lin PL, Darville T. Chronic granulomatous disease in an adolescent with recurrent impetigo and cholecystectomy. Pediatr Infect Dis J. 2009 Mar; 28(3):255-7.
  26. Kapadia SB, Macginnitie AJ, Shaw PH. X-linked lymphoproliferative disease in an EBV-negative patient presenting with pancytopenia. Pediatr Blood Cancer. 2008 Jun; 50(6):1296-7.
  27. MacGinnitie AJ, Walensky LD, Turvey SE, Orange JS, Bonilla FA, Silverman LB, Oettgen H. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003 Oct; 14(5):409-11.
  28. MacGinnitie AJ, Geha R. X-linked lymphoproliferative disease: genetic lesions and clinical consequences. Curr Allergy Asthma Rep. 2002 Sep; 2(5):361-7.
  29. Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, Tommerup N, Collins JE, Wright CL, Dunham I, MacGinnitie AJ, Davidson NO, Celis JE. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol. 1999 Aug; 113(2):162-9.
  30. Anant S, Martin SA, Yu H, MacGinnitie AJ, Devaney E, Davidson NO. A cytidine deaminase expressed in the post-infective L3 stage of the filarial nematode, Brugia pahangi, has a novel RNA-binding activity. Mol Biochem Parasitol. 1997 Sep; 88(1-2):105-14.
  31. MacGinnitie AJ, Anant S, Davidson NO. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J Biol Chem. 1995 Jun 16; 270(24):14768-75.
  32. Anant S, MacGinnitie AJ, Davidson NO. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem. 1995 Jun 16; 270(24):14762-7.
  33. Davidson NO, Anant S, MacGinnitie AJ. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr Opin Lipidol. 1995 Apr; 6(2):70-4.
  34. Anant S, MacGinnitie AJ, Davidson NO. The binding of apobec-1 to mammalian apo B RNA is stabilized by the presence of complementation factors which are required for post-transcriptional editing. Nucleic Acids Symp Ser. 1995; (33):99-102.
To schedule an appointment: Call 617-355-6117 or Request an Appointment


Boston Children’s is so much more than a hospital—it’s a community of researchers, clinicians, administrators, support staff, innovators, teachers, patients and families, all working together to make the impossible possible. ”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337